Sanofi licenses 5 drugs to Covis

04/8/2013 | Pharmaceutical Business Review Online · Drug Store News

Switzerland's Covis Pharma agreed to acquire the U.S. commercial rights to five drugs from Sanofi-Aventis and its units. The deal covers the prostate cancer drug Nilandron; Plaquenil, a drug for malaria, lupus and arthritis; amyotrophic lateral sclerosis drug Rilutek; Uroxatral, a drug for enlarged prostate; and high-potassium treatment Kayexalate. Sanofi keeps the products' rights elsewhere in the world.

View Full Article in:

Pharmaceutical Business Review Online · Drug Store News

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Market Intelligence Manager
Olympus Corporation of the Americas
Southborough, MA
Regulatory Counsel
Food and Drug Administration
Silver Spring, MD
Pharmacy Care Manager
National Association of Chain Drug Stores
Arlington, VA
Vice President, Commercial Markets
Meridian Health
Neptune, NJ
Health Plan CEO – Oregon
Trillium Community Health Plan
Eugene, OR